Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience.
| Publicado en: | Future Oncology Vol. 22; no. 19; pp. 2347 - 2367 |
|---|---|
| Autores principales: | , , , , |
| Formato: | Journal Article |
| Publicado: |
Taylor & Francis Ltd
Aug2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=196477648&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 196477648 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 14796694 3CMQ jtl: Future Oncology issn: 14796694 maglogo: N pubinfo: dt: Aug2026 vid: 22 iid: 19 pid: 377 pub: Taylor & Francis Ltd place: Philadelphia, Pennsylvania artinfo: ui: 196477648 10.1080/14796694.2026.2709201 196477648 ppf: 2347 ppct: 20 formats: tig: atl: Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience. aug: au: Babel, Riddhi A. Liu, Stephen V. Fan, Tao Amonkar, Mayur M. Velcheti, Vamsidhar affil: Value & Implementation Outcomes Research, Oncology, Merck & Co., Inc., Rahway, NJ, USA sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|